Ruben Malmberg

Ruben Malmberg is a researcher at Erasmus MC in the Department of Pharmacy, focusing on oncology, pharmacology, and health care economics. His work examines alternative dosing regimens for immune checkpoint inhibitors like pembrolizumab and nivolumab, emphasizing sustainability and cost-efficiency.

• Primary affiliation: Erasmus MC, Department of Pharmacy
• Research areas: Immune checkpoint inhibitors, carbon footprint analysis, drug administration optimization

Recent publications highlight trends in reducing health care emissions through subcutaneous monoclonal antibodies and economic comparisons of drug delivery systems. His studies also address real-world outcomes in non-small cell lung cancer treatment.

No scientific awards are explicitly mentioned in the provided data. Collaborations include institutions in oncology and health care research domains.